ISG15 blocks cardiac glycolysis and ensures sufficient mitochondrial energy production during Coxsackievirus B3 infection.

ISG15 ISGylation glycolysis metabolism mitochondrial function virus infection

Journal

Cardiovascular research
ISSN: 1755-3245
Titre abrégé: Cardiovasc Res
Pays: England
ID NLM: 0077427

Informations de publication

Date de publication:
03 Feb 2024
Historique:
received: 20 02 2023
revised: 10 11 2023
accepted: 12 12 2023
medline: 4 2 2024
pubmed: 4 2 2024
entrez: 3 2 2024
Statut: aheadofprint

Résumé

Virus infection triggers inflammation and, may impose nutrient shortage to the heart. Supported by type I interferon (IFN) signaling, cardiomyocytes counteract infection by various effector processes, with the IFN-stimulated gene of 15 kDa (ISG15) system being intensively regulated and protein modification with ISG15 protecting mice Coxsackievirus B3 (CVB3) infection. The underlying molecular aspects how the ISG15 system affects the functional properties of respective protein substrates in the heart are unknown. Based on the protective properties due to protein ISGylation, we set out a study investigating CVB3-infected mice in depth and found cardiac atrophy with lower cardiac output in ISG15-/- mice. By mass spectrometry, we identified the protein targets of the ISG15 conjugation machinery in heart tissue and explored how ISGylation affects their function. The cardiac ISGylome showed a strong enrichment of ISGylation substrates within glycolytic metabolic processes. Two control enzymes of the glycolytic pathway, hexokinase 2 (HK2) and phosphofructokinase muscle form (PFK1), were identified as bona fide ISGylation targets during infection. In an integrative approach complemented with enzymatic functional testing and structural modeling, we demonstrate that protein ISGylation obstructs the activity of HK2 and PFK1. Seahorse-based investigation of glycolysis in cardiomyocytes revealed that, by conjugating proteins, the ISG15 system prevents the infection-/IFN-induced upregulation of glycolysis. We complemented our analysis with proteomics-based advanced computational modeling of cardiac energy metabolism. Our calculations revealed an ISG15-dependent preservation of the metabolic capacity in cardiac tissue during CVB3 infection. Functional profiling of mitochondrial respiration in cardiomyocytes and mouse heart tissue by Seahorse technology showed an enhanced oxidative activity in cells with a competent ISG15 system. Our study demonstrates that ISG15 controls critical nodes in cardiac metabolism. ISG15 reduces the glucose demand, supports higher ATP production capacity in the heart, despite nutrient shortage in infection, and counteracts cardiac atrophy and dysfunction.

Identifiants

pubmed: 38309955
pii: 7600410
doi: 10.1093/cvr/cvae026
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© The Author(s) 2024. Published by Oxford University Press on behalf of the European Society of Cardiology.

Auteurs

Clara Bredow (C)

Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Institute of Biochemistry, Berlin, Germany.

Fabien Thery (F)

Department of Biomolecular Medicine, Ghent University, Ghent, Belgium.
VIB-UGent Center for Medical Biotechnology, Ghent, Belgium.

Eva Katrin Wirth (EK)

Deutsches Zentrum für Herz-Kreislauf-Forschung, partner site Berlin, Berlin, Germany.
Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Endocrinology, Diabetes and Nutrition, Berlin, Germany.

Sarah Ochs (S)

Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Institute of Biochemistry, Berlin, Germany.

Meike Kespohl (M)

Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Institute of Biochemistry, Berlin, Germany.
Deutsches Zentrum für Herz-Kreislauf-Forschung, partner site Berlin, Berlin, Germany.

Gunnar Kleinau (G)

Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Institute of Medical Physics and Biophysics, Group Protein X-ray Crystallography and Signal Transduction, Charitéplatz 1, Berlin, Germany.

Nicolas Kelm (N)

Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Institute of Biochemistry, Berlin, Germany.

Niclas Gimber (N)

Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Advanced Medical Bioimaging Core Facility, Berlin, Germany.

Jan Schmoranzer (J)

Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Advanced Medical Bioimaging Core Facility, Berlin, Germany.

Martin Voss (M)

Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Institute of Biochemistry, Berlin, Germany.

Karin Klingel (K)

University of Tübingen, Cardiopathology, Institute for Pathology and Neuropathology, Tübingen, Germany.

Joachim Spranger (J)

Deutsches Zentrum für Herz-Kreislauf-Forschung, partner site Berlin, Berlin, Germany.
Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Endocrinology, Diabetes and Nutrition, Berlin, Germany.

Kostja Renko (K)

German Federal Institute for Risk Assessment (BfR), German Centre for the Protection of Laboratory Animals (Bf3R), Berlin, Germany.

Markus Ralser (M)

Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Core Facility - High-Throughput Mass Spectrometry, Berlin, Germany.

Michael Mülleder (M)

Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Core Facility - High-Throughput Mass Spectrometry, Berlin, Germany.

Arnd Heuser (A)

Animal Phenotyping Platform, Max-Delbrueck-Center for Molecular Medicine, Berlin, Germany.

Klaus-Peter Knobeloch (KP)

University of Freiburg, Institute of Neuropathology, Freiburg, Germany.
CIBSS - Centre for Integrative Biological Signalling Studies, University of Freiburg, Freiburg, Germany.

Patrick Scheerer (P)

Deutsches Zentrum für Herz-Kreislauf-Forschung, partner site Berlin, Berlin, Germany.
Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Institute of Medical Physics and Biophysics, Group Protein X-ray Crystallography and Signal Transduction, Charitéplatz 1, Berlin, Germany.

Jennifer Kirwan (J)

Berlin Institute of Health (BIH) @ Charité, Metabolomics Platform, Berlin, Germany.
Max-Delbrück-Center (MDC) for Molecular Medicine, Berlin, Germany.
Berlin Institute of Health (BIH), Berlin, Germany.

Ulrike Brüning (U)

Berlin Institute of Health (BIH) @ Charité, Metabolomics Platform, Berlin, Germany.
Max-Delbrück-Center (MDC) for Molecular Medicine, Berlin, Germany.
Berlin Institute of Health (BIH), Berlin, Germany.

Nikolaus Berndt (N)

Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Institute for Computational and Imaging Science in Cardiovascular Medicine, Berlin, Germany.

Francis Impens (F)

Department of Biomolecular Medicine, Ghent University, Ghent, Belgium.
VIB-UGent Center for Medical Biotechnology, Ghent, Belgium.
VIB Proteomics Core, Ghent, Belgium.

Antje Beling (A)

Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Institute of Biochemistry, Berlin, Germany.
Deutsches Zentrum für Herz-Kreislauf-Forschung, partner site Berlin, Berlin, Germany.

Classifications MeSH